A new pill, tavapadon, has shown potential in easing Parkinson’s symptoms while limiting side effects. In patients taking at ...

For patients with Parkinson disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time vs placebo.

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

As one of the leading facilities for advanced neurological and Parkinson’s care in the region, King’s College Hospital Dubai ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...

Two early-phase clinical trials demonstrate the safety and potential clinical utility of stem cell therapies to ease motor ...

BioVie (BIVI) announced that patient enrollment is now open for the Phase 2 SUNRISE-PD clinical trial evaluating the safety and efficacy of ...

New hope as surprising Parkinson’s treatment deemed safe in clinical trials - More than 150,000 people in the UK are living ...

The annual meeting of the American Academy of Neurology was held this year from April 5 to 9 in San Diego. Participants ...

Stem cell therapies for Parkinson’s deemed safe in clinical trials - The studies also ‘offer hope’ that transplanted cells ...